Equillium, Inc. (NASDAQ:EQ) Sees Significant Decline in Short Interest

Equillium, Inc. (NASDAQ:EQ) was the recipient of a significant decline in short interest during the month of February. As of February 28th, there was short interest totalling 363,900 shares, a decline of 45.9% from the February 13th total of 672,300 shares. Approximately 2.1% of the shares of the stock are short sold. Based on an average daily volume of 770,000 shares, the short-interest ratio is presently 0.5 days.

Equillium Price Performance

NASDAQ:EQ traded down $0.03 during mid-day trading on Friday, reaching $0.75. 111,892 shares of the company’s stock traded hands, compared to its average volume of 365,234. The company has a 50 day moving average price of $0.76 and a 200-day moving average price of $0.81. The firm has a market capitalization of $26.75 million, a price-to-earnings ratio of -5.39 and a beta of 1.87. Equillium has a 12-month low of $0.49 and a 12-month high of $2.99.

Institutional Trading of Equillium

An institutional investor recently raised its position in Equillium stock. DCF Advisers LLC increased its stake in Equillium, Inc. (NASDAQ:EQ) by 91.0% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 62,947 shares of the company’s stock after purchasing an additional 29,985 shares during the quarter. DCF Advisers LLC owned approximately 0.18% of Equillium worth $47,000 at the end of the most recent quarter. Institutional investors own 27.05% of the company’s stock.

Equillium Company Profile

Equillium, Inc, a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis.